Download PDF
Thorac Cardiovasc Surg 2009; 57(8): 472-475
DOI: 10.1055/s-0029-1185734
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

Early Recurrence after Surgical Resection in Patients with Pathological Stage I Non-small Cell Lung Cancer

R. Kawachi1 , H. Tsukada1 , Y. Nakazato1 , H. Takei1 , G. Furuyashiki1 , Y. Koshi-ishi1 , T. Goya1
  • 1Thoracic Surgery, Kyorin University Hospital, Tokyo, Japan
Further Information

Publication History

received Nov. 24, 2008

Publication Date:
14 December 2009 (online)

    Permissions and Reprints All articles of this category

Abstract

Introduction: Early recurrence is observed even in patients who undergo complete resection and had pathological (p-) stage I. Therefore, we focused on early recurrence, and attempted to elucidate the relationship between early recurrence and clinicopathological factors. Methods: Between May 1993 and December 2005, 1201 patients with non-small cell lung cancer (NSCLC) underwent surgical treatment at our institution. Of these, 402 patients who underwent complete resection and had p-stage I NSCLC were retrospectively analyzed for clinicopathological factors. Patients were divided into four groups according to the period between surgery and recurrence (R): no recurrence (NR, n = 331), late recurrence (LR, n = 28, R > 2 years), intermediate recurrence (IR, n = 22, 1 year < R ≤ 2 years), and early recurrence (ER, n = 21, R ≤ 1 year). Results: The overall 5-year survival rate for patients with p-stage I was 79.9 %. The overall 5-year survival rates were 91.0 %, 55.6 %, 17.1 %, and 7.5 % for the NR, LR, IR, and ER group, respectively. Preoperative high CEA level, lymphatic permeation, and pleural invasion were proven to be independent factors for overall recurrence. Moreover, multivariate analysis showed that preoperative CEA level, pathological T factor, lymphatic permeation, vascular invasion, and pleural invasion influenced early recurrence within one year. Conclusions: The present study demonstrated that preoperative CEA level, pathological T-factor, lymphatic permeation, vascular invasion, and pleural invasion were independent prognostic factors for early recurrence within one year, even in patients with pathological stage I. In patients with these factors, adjuvant therapy may be indicated since this may improve their survival.

Key words

thoracic surgery - lung cancer - carcinoembryonic antigen - recurrence - adjuvant therapy - survival

References

  • 1 Martini N, Bains M S, Burt M E, Zakowski M F, McCormack P, Rusch V W, Ginsberg R J. Incidence of local recurrence and second primary tumors in resected stage I lung cancer.  J Thorac Cardiovasc Surg. 1995;  109 (1) 120-129
    CrossrefPubMedGoogle Scholar
  • 2 Harpole Jr D H, Herndon 2nd J E, Young Jr W G, Wolfe W G, Sabiston Jr D C. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.  Cancer. 1995;  76 (5) 787-796
    CrossrefPubMedGoogle Scholar
  • 3 Douillard J Y, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba J L, Grodzki T, Pereira J R, Le Groumellec A, Lorusso V, Clary C, Torres A J, Dahabreh J, Souquet P J, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. ANITA adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.  Lancet Oncol. 2006;  7 (9) 719-727
    CrossrefPubMedGoogle Scholar
  • 4 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J P, Vansteenkiste J. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.  N Engl J Med. 2004;  350 (4) 351-360
    CrossrefPubMedGoogle Scholar
  • 5 Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.  N Engl J Med. 2004;  350 (17) 1713-1721
    CrossrefPubMedGoogle Scholar
  • 6 International Union Against Cancer .Lung tumours. Sobin LH, Wittekind CH TNM classification of malignant tumours. 6th ed. New York; Wiley-Liss 2002
    PubMedGoogle Scholar
  • 7 Travis W D, Colby T V, Corrin B et al. Histological typing of lung and pleural tumors; World Health Organization international histological classification of tumors. Berlin; Springer 1999
    PubMedGoogle Scholar
  • 8 Rubins J B, Dunitz J, Rubins H B, Maddaus M A, Niewoehner D E. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer.  J Thorac Cardiovasc Surg. 1998;  116 (3) 412-416
    CrossrefPubMedGoogle Scholar
  • 9 Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, Maeda H. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer.  Ann Thorac Surg. 2002;  74 (1) 174-179
    CrossrefPubMedGoogle Scholar
  • 10 Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test.  Ann Thorac Surg. 2003;  75 (3) 973-980
    CrossrefPubMedGoogle Scholar
  • 11 Takamochi K, Yoshida J, Nishimura M, Yokose T, Sasaki S, Nishiwaki Y, Suzuki K, Nagai K. Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings.  Eur J Cardiothorac Surg. 2004;  25 (5) 877-883
    CrossrefPubMedGoogle Scholar
  • 12 Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.  Ann Thorac Surg. 2004;  78 (3) 1004-1009
    CrossrefPubMedGoogle Scholar
  • 13 Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society.  Am J Respir Crit Care Med. 1997;  156 (1) 320-332
    CrossrefPubMedGoogle Scholar
  • 14 Depierre A, Lagrange J L, Theobald S, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Bréchot J M, Breton J L, Douillard J Y, Grivaux M, Jacoulet P, Khalil A, Lemarié E, Martinet Y, Massard G, Milleron B, Molina T, Moro-Sibilot D, Paesmans M, Pujol J L, Quoix E, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet P J, Spaeth D, Stoebner-Delbarre A, Thiberville L, Touboul E, Vaylet F, Vergnon J M, Westeel V. FNCLCC . Summary report of the standards, options and recommendations for the management of patients with non-small-cell lung carcinoma (2000).  Br J Cancer. 2003;  89 (Suppl. 1) S35-S49
    CrossrefPubMedGoogle Scholar
  • 15 Silvestri G A, Gould M K, Margolis M L, Tanoue L T, McCrory D, Toloza E, Detterbeck F. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition).  Chest. 2007;  132 (Suppl. 3) 178S-201S
    CrossrefPubMedGoogle Scholar

Dr. Riken Kawachi

Division of Thoracic Surgery, Department of Surgery
Kyorin University School of Medicine

6-20-2 Shinkawa, Mitaka-shi

181-8611 Tokyo

Japan

Phone: + 81 4 22 47 55 11

Fax: + 81 4 22 44 35 76

Email: rkawachi@kpe.biglobe.ne.jp

      >